FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113011364> ?p ?o ?g. }

• W2113011364 endingPage "44" @default.
• W2113011364 startingPage "37" @default.
• W2113011364 abstract "Patients with advanced Parkinson's disease often have rapid swings between mobility and immobility, and many respond unsatisfactorily to adjustments in pharmacological treatment. We assessed whether globus pallidus pars interna (GPi) deep brain stimulation (DBS) gives greater functional improvement than does subthalamic nucleus (STN) DBS.We recruited patients from five centres in the Netherlands who were aged 18 years or older, had idiopathic Parkinson's disease, and had, despite optimum pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonias, or bradykinesia. By use of a computer-generated randomisation sequence, we randomly assigned patients to receive either GPi DBS or STN DBS (1:1), applying a minimisation procedure according to drug use (levodopa equivalent dose <1000 mg vs ≥1000 mg) and treatment centre. Patients and study assessors (but not those who assessed adverse events) were masked to treatment allocation. We had two primary outcomes: functional health as measured by the weighted Academic Medical Center Linear Disability Scale (ALDS; weighted by time spent in the off phase and on phase) and a composite score for cognitive, mood, and behavioural effects up to 1 year after surgery. Secondary outcomes were symptom scales, activities of daily living scales, a quality-of-life questionnaire, the occurrence of adverse events, and drug use. We used the intention-to-treat principle for all analyses. This trial is registered with www.controlled-trials.com, number ISRCTN85542074.Between Feb 1, 2007, and March 29, 2011, we enrolled 128 patients, assigning 65 to GPi DBS and 63 to STN DBS. We found no statistically significant difference in either of our primary outcomes: mean change in weighted ALDS (3·0 [SD 14·5] in the GPi group vs 7·7 [23·2] in the STN group; p=0·28) and the number of patients with cognitive, mood, and behavioural side-effects (36 [58%] of 62 patients in the GPi group vs 35 [56%] of 63 patients in the STN group; p=0·94). Secondary outcomes showed larger improvements in off-drug phase in the STN group compared with the GPi group in the mean change in unified Parkinson's disease rating scale motor examination scores (20·3 [16·3] vs 11·4 [16·1]; p=0·03), the mean change in ALDS scores (20·3 [27·1] vs 11·8 [18·9]; p=0·04), and medication (mean levodopa equivalent drug reduction: 546 [SD 561] vs 208 [521]; p=0·01). We recorded no difference in the occurrence of adverse events between the two groups. Other secondary endpoints showed no difference between the groups.Although there was no difference in our primary outcomes, our findings suggest that STN could be the preferred target for DBS in patients with advanced Parkinson's disease.Stichting Internationaal Parkinson Fonds, Prinses Beatrix Fonds, and Parkinson Vereniging." @default.
• W2113011364 created "2016-06-24" @default.
• W2113011364 creator A5003902104 @default.
• W2113011364 creator A5005646056 @default.
• W2113011364 creator A5006053190 @default.
• W2113011364 creator A5006306099 @default.
• W2113011364 creator A5008483577 @default.
• W2113011364 creator A5008585730 @default.
• W2113011364 creator A5015826135 @default.
• W2113011364 creator A5028185123 @default.
• W2113011364 creator A5037860381 @default.
• W2113011364 creator A5049934672 @default.
• W2113011364 creator A5052156791 @default.
• W2113011364 creator A5061133667 @default.
• W2113011364 creator A5066702343 @default.
• W2113011364 creator A5066754936 @default.
• W2113011364 creator A5081276302 @default.
• W2113011364 creator A5083387295 @default.
• W2113011364 creator A5089995737 @default.
• W2113011364 date "2013-01-01" @default.
• W2113011364 modified "2023-10-10" @default.
• W2113011364 title "Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial" @default.
• W2113011364 cites W1999151548 @default.
• W2113011364 cites W1999634839 @default.
• W2113011364 cites W2006826552 @default.
• W2113011364 cites W2016922632 @default.
• W2113011364 cites W2023115945 @default.
• W2113011364 cites W2041173453 @default.
• W2113011364 cites W2043796909 @default.
• W2113011364 cites W2049483623 @default.
• W2113011364 cites W2061522482 @default.
• W2113011364 cites W2075449392 @default.
• W2113011364 cites W2079628098 @default.
• W2113011364 cites W2095270577 @default.
• W2113011364 cites W2099944633 @default.
• W2113011364 cites W2105501880 @default.
• W2113011364 cites W2113491613 @default.
• W2113011364 cites W2119253626 @default.
• W2113011364 cites W2124227727 @default.
• W2113011364 cites W2127149676 @default.
• W2113011364 cites W2139142117 @default.
• W2113011364 cites W2141263267 @default.
• W2113011364 cites W2149476088 @default.
• W2113011364 cites W2153382660 @default.
• W2113011364 cites W2153569137 @default.
• W2113011364 cites W2156423414 @default.
• W2113011364 cites W2165828096 @default.
• W2113011364 cites W2166562076 @default.
• W2113011364 cites W2169247253 @default.
• W2113011364 cites W2328435466 @default.
• W2113011364 cites W3025643029 @default.
• W2113011364 cites W4235813114 @default.
• W2113011364 doi "https://doi.org/10.1016/s1474-4422(12)70264-8" @default.
• W2113011364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23168021" @default.
• W2113011364 hasPublicationYear "2013" @default.
• W2113011364 type Work @default.
• W2113011364 sameAs 2113011364 @default.
• W2113011364 citedByCount "544" @default.
• W2113011364 countsByYear W21130113642012 @default.
• W2113011364 countsByYear W21130113642013 @default.
• W2113011364 countsByYear W21130113642014 @default.
• W2113011364 countsByYear W21130113642015 @default.
• W2113011364 countsByYear W21130113642016 @default.
• W2113011364 countsByYear W21130113642017 @default.
• W2113011364 countsByYear W21130113642018 @default.
• W2113011364 countsByYear W21130113642019 @default.
• W2113011364 countsByYear W21130113642020 @default.
• W2113011364 countsByYear W21130113642021 @default.
• W2113011364 countsByYear W21130113642022 @default.
• W2113011364 countsByYear W21130113642023 @default.
• W2113011364 crossrefType "journal-article" @default.
• W2113011364 hasAuthorship W2113011364A5003902104 @default.
• W2113011364 hasAuthorship W2113011364A5005646056 @default.
• W2113011364 hasAuthorship W2113011364A5006053190 @default.
• W2113011364 hasAuthorship W2113011364A5006306099 @default.
• W2113011364 hasAuthorship W2113011364A5008483577 @default.
• W2113011364 hasAuthorship W2113011364A5008585730 @default.
• W2113011364 hasAuthorship W2113011364A5015826135 @default.
• W2113011364 hasAuthorship W2113011364A5028185123 @default.
• W2113011364 hasAuthorship W2113011364A5037860381 @default.
• W2113011364 hasAuthorship W2113011364A5049934672 @default.
• W2113011364 hasAuthorship W2113011364A5052156791 @default.
• W2113011364 hasAuthorship W2113011364A5061133667 @default.
• W2113011364 hasAuthorship W2113011364A5066702343 @default.
• W2113011364 hasAuthorship W2113011364A5066754936 @default.
• W2113011364 hasAuthorship W2113011364A5081276302 @default.
• W2113011364 hasAuthorship W2113011364A5083387295 @default.
• W2113011364 hasAuthorship W2113011364A5089995737 @default.
• W2113011364 hasConcept C118552586 @default.
• W2113011364 hasConcept C126322002 @default.
• W2113011364 hasConcept C168563851 @default.
• W2113011364 hasConcept C1862650 @default.
• W2113011364 hasConcept C197934379 @default.
• W2113011364 hasConcept C2777319143 @default.
• W2113011364 hasConcept C2778187257 @default.
• W2113011364 hasConcept C2778542668 @default.
• W2113011364 hasConcept C2779134260 @default.
• W2113011364 hasConcept C2779734285 @default.

• next